What are the considerations for using mefenamic acid in a patient with asthma (Asthma) or Chronic Obstructive Pulmonary Disease (COPD) and a salbutamol (albuterol) allergy, presenting with a chronic cough?

Mefenamic Acid Use in Asthma/COPD with Salbutamol Allergy and Chronic Cough

Mefenamic acid is absolutely contraindicated in this patient and should never be prescribed. 1

Critical Contraindication

Mefenamic acid is explicitly contraindicated in patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, as severe and sometimes fatal anaphylactic reactions have been reported. 1 The FDA label specifically warns that cross-reactivity between aspirin and other NSAIDs has been documented in aspirin-sensitive patients, and mefenamic acid can cause severe, potentially fatal bronchospasm in patients with aspirin-sensitive asthma. 1

Additional Respiratory Risks

• Aspirin-sensitive asthma may include chronic rhinosinusitis with nasal polyps, severe bronchospasm, and intolerance to NSAIDs—mefenamic acid is contraindicated in this population. 1
• Even in patients with pre-existing asthma without known aspirin sensitivity, mefenamic acid requires monitoring for changes in asthma symptoms, though this does not apply when the drug is contraindicated. 1
• The patient's documented salbutamol (albuterol) allergy suggests heightened respiratory sensitivity and potential cross-reactivity with other medications affecting airways. 1

Alternative Approach to Chronic Cough Management

For Asthma-Related Cough

Initiate treatment with inhaled corticosteroids as first-line therapy, avoiding all beta-agonists given the documented salbutamol allergy. 2, 3

• Ipratropium bromide (anticholinergic bronchodilator) should be the primary bronchodilator choice instead of beta-agonists, with Grade A evidence for improving cough in chronic bronchitis. 4, 5
• Standard dosing: ipratropium bromide 36 μg (2 inhalations) four times daily. 5
• If cough persists despite inhaled corticosteroids and ipratropium, add a leukotriene receptor antagonist (LTRA) before escalating to systemic corticosteroids. 2, 3
• For severe/refractory cough, prescribe a short course (1-2 weeks) of oral corticosteroids followed by inhaled corticosteroids. 2

For COPD-Related Cough

Ipratropium bromide remains the preferred first-line treatment with Grade A recommendation, demonstrating reduction in cough frequency, severity, and sputum volume. 4, 5

• If bronchospasm control is inadequate with ipratropium alone, consider theophylline (requires monitoring for narrow therapeutic index and drug interactions). 4, 5
• Avoid short-acting beta-agonists entirely given the documented allergy. 4
• For symptomatic relief when cough severely impacts quality of life despite optimal bronchodilator therapy, consider centrally-acting antitussives (codeine or dextromethorphan), which reduce cough counts by 40-60% in chronic bronchitis. 5

Diagnostic Priorities

• Perform spirometry with bronchodilator responsiveness testing using ipratropium (not salbutamol) to confirm reversible airflow obstruction. 6
• Measure FEV1 before and after ipratropium inhalation rather than relying on single peak expiratory flow measurements. 6
• Consider sputum eosinophil counts or fractional exhaled nitric oxide (FeNO) to assess airway inflammation and guide corticosteroid therapy intensity. 3
• Exclude alternative causes: post-nasal drip, gastroesophageal reflux, ACE inhibitor use, or non-asthmatic eosinophilic bronchitis. 3, 7

Critical Pitfalls to Avoid

• Never prescribe NSAIDs (including mefenamic acid) to patients with asthma and documented drug allergies affecting respiratory medications. 1
• Do not attempt empiric beta-agonist trials in patients with documented salbutamol allergy—this risks anaphylaxis and delays appropriate diagnosis. 6, 7
• Avoid expectorants as they lack proven efficacy for cough in chronic bronchitis. 4, 5
• Do not use theophylline during acute exacerbations of chronic bronchitis (Grade D recommendation). 4
• Ensure proper inhaler technique for optimal anticholinergic delivery, as inadequate technique is a common cause of treatment failure. 5